GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaTher Holdings Ltd (XCNQ:PHRM) » Definitions » Change In Working Capital

PharmaTher Holdings (XCNQ:PHRM) Change In Working Capital : C$-0.31 Mil (TTM As of Feb. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PharmaTher Holdings Change In Working Capital?

PharmaTher Holdings's change in working capital for the quarter that ended in Feb. 2024 was C$-0.34 Mil.

PharmaTher Holdings's change in working capital for the fiscal year that ended in May. 2023 was C$0.55 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).


PharmaTher Holdings Change In Working Capital Historical Data

The historical data trend for PharmaTher Holdings's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaTher Holdings Change In Working Capital Chart

PharmaTher Holdings Annual Data
Trend May21 May22 May23
Change In Working Capital
0.19 0.18 0.55

PharmaTher Holdings Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.35 -0.07 -0.25 -0.34

PharmaTher Holdings Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.31 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaTher Holdings Change In Working Capital Related Terms

Thank you for viewing the detailed overview of PharmaTher Holdings's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaTher Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.
Executives
Fabio Chianelli Director, Senior Officer

PharmaTher Holdings Headlines

No Headlines